Skip to main content

Table 2 Risk exposure factors and prevention practices regarding HBV, HCV and HIV in BaroTest and 2016-Health Barometer samples, mainland France, 2016

From: HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

Characteristics BaroTest (eligible, n = 17,781) 2016-HB (n = 20,032)
Participants
(n = 6,945)
  Non participants
(n = 10,836)
 
wBT % a wHB %a   wHB %a wHB %a
HCV endemicity in country of birthb Low 91.1 94.8 *** 91.4 92.4
Intermediate or high 8.9 5.2   8.6 7.6
HBV endemicity in country of birthc Low 86.6 91.8 *** 86.8 88.4
Intermediate 10.2 6.2   9.7 8.4
High 3.2 2.0   3.5 3.2
Healthcare or stays ≥3 months in Africa, Asia or Middle East Yes 12.6 11.0 * 12.5 11.9
No 87.4 89.0   87.5 88.1
Blood transfusion before 1992 Yes 6.3 6.8   6.2 6.0
No 92.7 92.4   92.7 93.0
Not specified 1.0 0.8   1.1 1.0
Drug use during lifetime Yes, intravenous use with or without nasal use 0.6 0.5   0.4 0.4
Yes, nasal use only 5.9 5.2   4.7 4.8
No 93.5 94.3   94.9 94.8
Lived with or had sexual intercourse with an HBV-infected person Yes 4.3 3.9   3.4 3.6
No 95.3 95.8   96.2 96.0
Not specified 0.4 0.3   0.4 0.4
Sex with other men during lifetimed Yes 3.8 3.7   3.9 3.7
No 96.1 96.2   95.7 96.0
Not specified 0.1 0.1   0.4 0.3
Sexually transmitted infection(s) in the previous 12 monthse Yes 1.3 1.1   1.0 1.1
No 98.7 98.9   99.0 98.9
Tattooing or piercing without single-use materials Yes 2.1 2.0   2.1 2.0
No 97.9 98.0   97.9 98.0
HCV screening during lifetime Yes 19.9 19.2   19.8 19.2
No 76.2 77.0   76.4 76.9
Not specified 3.9 3.8   3.8 3.9
HBV screening during lifetime Yes 37.4 37.1 * 36.5 35.6
No 59.2 59.5   60.9 61.4
Not specified 3.4 3.4   2.6 3.0
HIV screening during lifetime Yes 60.3 60.0 *** 56.7 57.8
No 39.4 39.7   43.0 41.9
Not specified 0.3 0.3   0.3 0.3
HBV vaccination Yes 47.8 47.0 *** 44.7 46.1
No 45.9 47.3   48.0 46.6
Not specified 6.3 5.7   7.3 7.3
  1. * P-value < 0.05, ** P value < 0.01, *** P value < 0.001 between BaroTest participants and non-participants wHB distributions using Chi-2 test
  2. awHB %: Health Barometer weighted percentage; wBT %: BaroTest weighted percentage
  3. bCountries with a low level of HCV endemicity: Europe, America, Caribbean; countries with an intermediate or high level of endemicity: Africa, Middle-East, Indian subcontinent, Asia, Pacific Islands
  4. cCountries with a low level of HBV endemicity: Northern and Western Europe, North America, Pacific Islands; countries with an intermediate level of endemicity: French Overseasadministrative areas, Eastern and Southern Europe, North Africa, Middle-East, Indian subcontinent, South America; countries with a high level of endemicity: Sub-Saharan Africa, Asia
  5. dAmong men who reported having had sexual relations in their lifetime (with men or women)
  6. eAmong individuals who reported having already had sexual relations in their lifetime. Mycosis are excluded
  7. The distributions are significantly different for numbers in bold